Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

WPD Pharmaceuticals Inc WPDPF


Primary Symbol: C.WBIO

Industrials Technology
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.


CSE:WBIO - Post by User

WPD Pharmaceuticals Inc
<< Previous
 Bullboard Posts
User Avatar Image
(1931)
•••
Post by Betteryear2on Mar 07, 2022 7:57am
158 Views
Post# 34489403

Signs Consortium Agreement on EuroNanoMed Project

Signs Consortium Agreement on EuroNanoMed Project

VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has received the final version of the signed Consortium Agreement related to the EuroNanoMed Project. The consortium will research the potential of AGuIX® nanoparticles in maximizing radiotherapy efficiency and explore two of WPD’s compounds specifically to restore GBM cells' sensitivity to radiotherapy.

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities